| ID Source | ID |
|---|---|
| PubMed CID | 5702678 |
| SCHEMBL ID | 20561279 |
| MeSH ID | M0593906 |
| Synonym |
|---|
| disodium;(6e)-4-amino-3-[[4-[4-[(2,4-diaminophenyl)diazenyl]phenyl]phenyl]diazenyl]-5-oxo-6-(phenylhydrazinylidene)naphthalene-2,7-disulfonate |
| SCHEMBL20561279 |
| chlorazolblacke |
| ferristatin ii |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Ferristatin II did not cause degradation of DMT1 but did induce DMT1 internalization from the plasma membrane." | ( Inhibition of iron uptake by ferristatin II is exerted through internalization of DMT1 at the plasma membrane. Kishi, F; Noguchi, Y; Yanatori, I; Yasui, Y, 2015) | 1.43 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Rats treated with ferristatin II have lower TfR1 in liver." | ( Ferristatin II promotes degradation of transferrin receptor-1 in vitro and in vivo. Buckett, PD; Byrne, SL; Chen, J; Enns, C; Kim, J; Luo, F; Sanford, J; Wessling-Resnick, M, 2013) | 2.16 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.22) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||